000272883 001__ 272883
000272883 005__ 20250127091429.0
000272883 0247_ $$2pmc$$apmc:PMC11514856
000272883 0247_ $$2doi$$a10.1186/s40164-024-00576-6
000272883 0247_ $$2pmid$$apmid:39468695
000272883 037__ $$aDZNE-2024-01299
000272883 041__ $$aEnglish
000272883 082__ $$a610
000272883 1001_ $$aPu, Jingjing$$b0
000272883 245__ $$aAdvances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma.
000272883 260__ $$aLondon$$bBiomed Central$$c2024
000272883 3367_ $$2DRIVER$$aarticle
000272883 3367_ $$2DataCite$$aOutput Types/Journal article
000272883 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1731075428_3251$$xReview Article
000272883 3367_ $$2BibTeX$$aARTICLE
000272883 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000272883 3367_ $$00$$2EndNote$$aJournal Article
000272883 520__ $$aThe basic idea of modulating the immune system to better recognize and fight tumor cells has led to the successful introduction of adoptive cellular immunotherapy (ACT). ACT-based treatment regimens, in which the patient's own immune cells are isolated and subsequently expanded (ex vivo) and reinfused, have also contributed significantly to the development of a personalized treatment strategy. Complementing this, the unprecedented advances in ACTs as chimeric antigen receptor (CAR)-T cell therapies and their derivatives such as CAR-NK, CAR-macrophages, CAR-γδT and CAR-NKT have further maximized the therapeutic outcomes. Herein, we provide a comprehensive overview of the development of ACTs in multiple myeloma (MM) and outline how they have evolved from an experimental form to a mainstay of standard clinical settings. Besides, we provide insights into cytokine-induced killer cell (CIK) therapy, an alternative form of ACT that (as CIK or CAR-CIK) has enormous potential in the clinical spectrum of MM. We also summarize the results of the major preclinical and clinical studies of adoptive cell therapy in MM and address the current challenges (such as cytokine release syndrome (CRS) and neurotoxicity) that limit its complete success in the cancer landscape.
000272883 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000272883 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000272883 650_7 $$2Other$$aCAR-NK
000272883 650_7 $$2Other$$aCAR-T
000272883 650_7 $$2Other$$aCIK
000272883 650_7 $$2Other$$aCell therapy
000272883 650_7 $$2Other$$aImmunotherapy
000272883 650_7 $$2Other$$aMultiple myeloma
000272883 7001_ $$0P:(DE-2719)9002571$$aLiu, Ting$$b1$$eFirst author$$udzne
000272883 7001_ $$aSharma, Amit$$b2
000272883 7001_ $$aJiang, Liping$$b3
000272883 7001_ $$aWei, Feng$$b4
000272883 7001_ $$aRen, Xiubao$$b5
000272883 7001_ $$aSchmidt-Wolf, Ingo G H$$b6
000272883 7001_ $$aHou, Jian$$b7
000272883 773__ $$0PERI:(DE-600)2669066-4$$a10.1186/s40164-024-00576-6$$gVol. 13, no. 1, p. 105$$n1$$p105$$tExperimental hematology & oncology$$v13$$x2162-3619$$y2024
000272883 8564_ $$uhttps://pub.dzne.de/record/272883/files/DZNE-2024-01299.pdf$$yOpenAccess
000272883 8564_ $$uhttps://pub.dzne.de/record/272883/files/DZNE-2024-01299.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000272883 909CO $$ooai:pub.dzne.de:272883$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000272883 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002571$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000272883 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000272883 9141_ $$y2024
000272883 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-22
000272883 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-22
000272883 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-22
000272883 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000272883 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-22
000272883 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEXP HEMATOL ONCOL : 2022$$d2023-08-22
000272883 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bEXP HEMATOL ONCOL : 2022$$d2023-08-22
000272883 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T15:11:21Z
000272883 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T15:11:21Z
000272883 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-22
000272883 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-22
000272883 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-22
000272883 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000272883 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-22
000272883 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-22
000272883 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-22
000272883 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-22
000272883 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-22
000272883 9201_ $$0I:(DE-2719)1013005$$kAG Ehninger$$lTranslational Biogerontology$$x0
000272883 980__ $$ajournal
000272883 980__ $$aVDB
000272883 980__ $$aUNRESTRICTED
000272883 980__ $$aI:(DE-2719)1013005
000272883 9801_ $$aFullTexts